· Aspen has clinched another deal with Johnson & Johnson to market COVID-19 vaccines under its own brand in Africa.
· An agreement between the two pharma leaders was signed that allows Aspen to package, sell and distribute Johnson & Johnson COVID 19 vaccines under its own brand.
Under its deal signed last year, with Johnson & Johnson ,the American multinational, South African pharma leader Aspen Pharmacare started packaging and filling vials of the U.S. company’s shots at a South African plant. It has delivered 180 million J&J vaccines since mid-2021.
Aspen has clinched another deal with Johnson & Johnson to market COVID-19 vaccines under its own brand in Africa .An agreement between the two pharma leaders was signed that allows Aspen to package, sell and distribute Johnson & Johnson COVID 19 vaccines under its own brand. According to a press release issued by J&J, the agreement allows Aspen to supply the COVID-19 vaccine under the Aspenovax brand to all 55 African countries and multilateral entities such as the African Vaccine Acquisition Trust and the COVAX Facility supporting Africa’s vaccination plan.To be specific, the South African manufacturer will receive drug substances from J&J, which will be used to produce finished, Aspen-branded vaccines for Africa.
Read More ;
https://trendsnafrica.com/
https://trendsnafrica.com/
https://trendsnafrica.com/
Aspen, in its statement said that the deal provides room to expand the agreement to include any new versions of the drug substance, such as those developed for new variants or a different formulation for administration as a booster. The agreement is expected to help Aspen develop expertise in making oncology and insulin medications as well as other inoculations.
It may be noted that the announcement comes just after Moderna, the J&J rival announced its deal with Kenya to build its first mRNA facility in Africa. Experts point out that the deal is significant from two aspects; Firstly, the Aspen branded shot would provide Africa with its first locally manufactured COVID-19 vaccine. Second, the deal would support Africa’s efforts to build its own local vaccine manufacturing capacity.
